You are here: Home » International » News » Companies
Business Standard

AstraZeneca betters estimates amid strong sales, Covid-19 vaccine hopes

The company reiterated that it was on track with late-stage trials for its coronavirus vaccine, which could be rolled out by the year-end

AstraZeneca | Coronavirus Vaccine | Coronavirus

Reuters  |  UK 

Initiate suitable prosecution steps against AstraZeneca management, pleads FMRI
AstraZeneca's Covid-19 shot is widely considered the leading candidate

Britain's bettered second-quarter sales and profit estimates on Thursday, thanks to strong sales during the lockdowns from the drugmaker's diverse product line-up, which now includes a front-running vaccine candidate.

Optimism over its vaccine has fuelled what was already a strong year for the company as it also stuck by its 2020 outlook. has gained from changes wrought by Chief Executive Pascal Soriot's focus on products and bets on newer medicines.

The company reiterated that it was on track with late-stage trials for its vaccine, which could be rolled out by the year-end.

Shares of London's most valuable listed company on Thursday rose 3% at 88.6 pounds after product sales of $6.05 billion in the three months ended June 30 surpassed analysts' consensus of $6.01 billion. The figure excludes payments from tie-ups.

Newer drugs for diabetes, heart conditions and cancer, including its top selling lung cancer drug Tagrisso, performed well in the quarter and remains on track for a third consecutive year of growth.

AstraZeneca has had a busy few months: it took on development of the shot from Oxford University, got billions in government funding, signed several supply deals, and was even the subject of a mega-merger speculation - all while marching on with its core business.

Among drugs with better-than-expected revenues, sales of respiratory drug Symbicort rose 12% to $653 million, about $90 million above consensus, while revenue from cancer drug Lynparza jumped 62% to $554 million.

There are no approved vaccines for the illness caused by the novel coronavirus, but AstraZeneca's shot is widely considered the leading candidate after results from early-stage human trials showed it was safe and produced an immune response.

Core earnings of 96 cents per share beat analysts' expectation of 93 cents. Total revenue rose 11%.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, July 30 2020. 15:20 IST